Evidence map›Paper›PMID 35056134›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

The First Dimeric Derivatives of the Glycopeptide Antibiotic Teicoplanin.

Ilona Bereczki, Zsolt Szűcs, Gyula Batta, Tamás Milán Nagy, Eszter Ostorházi, Katalin E Kövér, Anikó Borbás, Pál Herczegh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Strategic re-engineering of antibiotics.Nature reviews bioengineering · 2025
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ilona BereczkiDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.ORCID 0000-0003-4601-7257
Zsolt SzűcsDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.
Gyula BattaDepartment of Organic Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0002-0442-1828
Tamás Milán NagyDepartment of Inorganic and Analytical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0003-4766-1992
Eszter OstorháziDepartment of Medical Microbiology, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary.ORCID 0000-0002-9459-7316
Katalin E KövérDepartment of Inorganic and Analytical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0001-5020-4456
Anikó BorbásDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.ORCID 0000-0001-8462-4547
Pál HerczeghDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.

Funding

European Regional Development Fund GINOP-2.3.2-15-2016-00044European Regional Development Fund GINOP-2.3.4-15-2020-00008National Research, Development and Innovation Office of Hungary K128368
6 · The paper itself

Abstract

Various dimeric derivatives of the glycopeptide antibiotic teicoplanin were prepared with the aim of increasing the activity of the parent compound against glycopeptide-resistant bacteria, primarily vancomycin-resistant enterococci. Starting from teicoplanin, four covalent dimers were prepared in two orientations, using an α,ω-bis-isothiocyanate linker. Formation of a dimeric cobalt coordination complex of an

Indexed as

antibacterial activityCo(III) complexdimerDOSY NMRpseudoaglyconesynthesisteicoplanin

Identifiers

PMID35056134
PMCPMC8779952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.